Key result
All 105 clinical isolates of influenza A/H1N1 and A/H3N2 viruses from the 1988-1990 epidemics were susceptible to the antiviral action of rimantadine.
Influenza A/H1N1 and A/H3N2 isolates from the 1988-1990 epidemics remained susceptible to rimantadine in vitro.
Rimantadine-resistant H1N1 isolates warrant surveillance; leaves open clinical impact and treatment implications.
Clinical isolates of influenza A viruses identified during outbreaks in two winters were tested for their rimantadine susceptibilities by an enzyme-linked immunosorbent assay modified from that described previously by Belshe et al. (R. B. Belshe, B. Burk, F. Newman, R. L. Cerruti, and I. S. Sim, J. Virol. 62:1508-1512, 1988). The infectivity titer and the 50% inhibitory concentration of rimantadine were calculated for each virus. Of 105 influenza virus A isolates tested, 28 influenza A/H1N1 isolates from the 1988 and 1989 outbreak and 77 influenza A/H3N2 isolates from the outbreak in following year, were susceptible to the antiviral action of rimantadine.
No takes yet. Share an insight, caveat, or question.
Valette et al. (1993) studied Influenza A/H1N1 and A/H3N2 viruses (n=105). Rimantadine was evaluated on Susceptibility to the antiviral action of rimantadine. All 105 clinical isolates of influenza A/H1N1 and A/H3N2 viruses from the 1988-1990 epidemics were susceptible to the antiviral action of rimantadine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: